Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, March 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 205 articles: HTML format

Single Articles

1. WALLERSON J, Rostampour S, Teng S, Kidane D, et al
   Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment.
   J Cell Mol Med. 2026;30:e71064.
   PubMed    
   Abstract available
   
   

2. MELLEMA JJ, Stockem CF, Herberts C, Cheung SK, et al
   Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
   Nat Med. 2026 Feb 27. doi: 10.1038/s41591-026-04271.
   PubMed    
   Abstract available
   
   

3. SHENG Y, Fan L, Zhu S, Wang Y, et al
   Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectomy.
   Urol Oncol. 2026;44:111039.
   PubMed    
   Abstract available
   
   

4. DENG Z, Yan Z, Chen Z
   Post-translational modifications: Principal regulators of bladder cancer.
   Mol Biol Rep. 2026;53:446.
   PubMed    
   
   
   

5. LI Y, Ma Y, Lai J, Wan Q, et al
   Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations.
   Discov Oncol. 2026 Feb 27. doi: 10.1007/s12672-025-04114.
   PubMed    
   
   
   

6. BENIJTS R, Akand M, Tipirdamaz M, Mennes J, et al
   External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.
   Minerva Urol Nephrol. 2026 Feb 27. doi: 10.23736/S2724-6051.25.06600.
   PubMed    
   Abstract available
   
   

7. YING X, Huang Y, Huang J, Cai Q, et al
   m(5)C-Modified tRF3b-Cys(GCA)-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.
   Adv Sci (Weinh). 2026 Feb 27:e22294. doi: 10.1002/advs.202522294.
   PubMed    
   Abstract available
   
   

8. MATSUO T, Mori S, Honda H, Kakita S, et al
   Preoperative Gamma-Glutamyltransferase-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
   Medicina (Kaunas). 2026;62:343.
   PubMed    
   Abstract available
   
   

9. PEREIRA M, Vale N
   Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.
   Genes (Basel). 2026;17:184.
   PubMed    
   Abstract available
   
   

10. SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
    Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction.
    Genes (Basel). 2026;17:153.
    PubMed    
    Abstract available
    
    

11. CAN VG
    Molecular Characterization of Muscle-Invasive Bladder Cancer: Key MicroRNAs, Transcription Factors, and Differentially Expressed Genes.
    Genes (Basel). 2026;17:122.
    PubMed    
    Abstract available
    
    

12. OZYURT N, Turhan A
    Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.
    Diagnostics (Basel). 2026;16:574.
    PubMed    
    Abstract available
    
    

13. PARADA D, Onoiu AI, Iftimie S, Camps J, et al
    A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer.
    Antioxidants (Basel). 2026;15:198.
    PubMed    
    Abstract available
    
    

14. BEKESCHUS S, Berner J, Edelmann J, Wolff CM, et al
    Synergistic Toxicity of Cold Gas Plasma and Cisplatin in Bladder Cancer Cells.
    Cancers (Basel). 2026;18:675.
    PubMed    
    Abstract available
    
    

15. GRIER AL, Zhong JY, Basourakos S, Calaway A, et al
    Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:623.
    PubMed    
    Abstract available
    
    

16. RIBEIRO E, Vale N
    Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.
    Cancers (Basel). 2026;18:562.
    PubMed    
    Abstract available
    
    

17. ZENG S, Xu Z, Xing S, Zhang Y, et al
    Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion.
    Eur J Med Res. 2026 Feb 26. doi: 10.1186/s40001-026-04029.
    PubMed    
    Abstract available
    
    

18. BAEK SW, Byun YJ, Piao XM, Seo JW, et al
    Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy.
    BMC Med. 2026 Feb 27. doi: 10.1186/s12916-026-04745.
    PubMed    
    Abstract available
    
    

19. HUANG GK, Zhang XX, Huang LY, Un HC, et al
    Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.
    J Transl Med. 2026 Feb 26. doi: 10.1186/s12967-026-07924.
    PubMed    
    Abstract available
    
    

20. REN S, Dai R, Zheng Z, Liu Q, et al
    Corrigendum to "A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer" [Nanomed Nanotechnol Biol Med 49 (April 2023) 102661].
    Nanomedicine. 2026 Feb 25:102916. doi: 10.1016/j.nano.2026.102916.
    PubMed    
    
    
    

21. SCHMID SC, Jahnen M, Schiller K, Sauter A, et al
    Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
    Eur Urol Oncol. 2026 Feb 25:S2588-9311(26)00056.
    PubMed    
    Abstract available
    
    

22. TRAN MA, Cho BA, Izadmehr S, Yoo SK, et al
    A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
    Cancer Discov. 2026 Feb 27. doi: 10.1158/2159-8290.CD-25-1774.
    PubMed    
    Abstract available
    
    

23. KATONGTUNG P, Shiangjen K, Cholamjiak W, Naravejsakul K, et al
    MRI-Based Bladder Cancer Staging via YOLOv11 Segmentation and Deep Learning Classification.
    Diseases. 2026;14:45.
    PubMed    
    Abstract available
    
    

24. PAVALEAN MI, Lambrescu IM, Gaina G, Madan VL, et al
    CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.
    Diseases. 2026;14:44.
    PubMed    
    Abstract available
    
    

25. BUONERBA C, Baio R, Crocetto F, Bruzzese D, et al
    BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.
    Curr Oncol. 2026;33:128.
    PubMed    
    Abstract available
    
    

26. ZHANG X, Su S, Liu L, Song F, et al
    Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1724968.
    PubMed    
    Abstract available
    
    

27. NIU S, Li L, Jia W, Feng H, et al
    Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.
    FEBS Open Bio. 2026 Feb 25. doi: 10.1002/2211-5463.70221.
    PubMed    
    Abstract available
    
    

28. HABICHER M, Swoboda C, Hauptmann A, Koch C, et al
    Enhanced recovery after radical cystectomy for bladder cancer: a prospective observational case -control study.
    BMC Urol. 2026 Feb 25. doi: 10.1186/s12894-026-02093.
    PubMed    
    
    
    

29. LEE TJ, Qiu L, Long J, Mach KE, et al
    CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.
    Sci Data. 2026 Feb 26. doi: 10.1038/s41597-026-06887.
    PubMed    
    Abstract available
    
    

30. TAKEUCHI M, Tamada T
    Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.
    Magn Reson Med Sci. 2026 Feb 26. doi: 10.2463/mrms.rev.2025-0213.
    PubMed    
    Abstract available
    
    

31. GUERRERO-RAMOS F
    BCG and Systemic Immunotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Lights and Shadows.
    Actas Urol Esp (Engl Ed). 2026 Feb 23:501936. doi: 10.1016/j.acuroe.2026.501936.
    PubMed    
    
    
    

32. WEI X, Cai L, Li N, Fang Y, et al
    High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics.
    Biosens Bioelectron. 2026;302:118545.
    PubMed    
    Abstract available
    
    

33. TRATNJEK L, Janev A, Kuret T, Jerman UD, et al
    The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.
    Front Immunol. 2026;17:1731784.
    PubMed    
    Abstract available
    
    

34. WANG Y, Wu N, Zhang S
    Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.
    Mol Cancer. 2026 Feb 24. doi: 10.1186/s12943-026-02608.
    PubMed    
    
    
    

35. ADIB E, Nassar AH, Alaiwi SA, Baca SC, et al
    Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.
    Mol Cancer Res. 2026 Feb 24. doi: 10.1158/1541-7786.MCR-25-1385.
    PubMed    
    Abstract available
    
    

36. GOEL V, Jain A, Basu D, Patnaik N, et al
    Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.
    Gulf J Oncolog. 2025;1:60-66.
    PubMed    
    Abstract available
    
    

37. SHAN M, Wang X, Wang Z, Xu C, et al
    NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.
    Bioact Mater. 2026;61:229-242.
    PubMed    
    Abstract available
    
    

38. HONG X, Wang G, Hong T, Liu X, et al
    Glycolysis-related genes for bladder cancer: A Mendelian randomization analysis.
    Biochem Biophys Rep. 2026;45:102501.
    PubMed    
    Abstract available
    
    

39. PEYROTTES A, Masson-Lecomte A, Aregui A, Meria P, et al
    [Specificities of oncologic surgery in elder patients].
    Rev Prat. 2026;76:60-65.
    PubMed    
    Abstract available
    
    

40. ZHANG L, Zhong Y, Yang G, Huang L, et al
    Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.
    Front Digit Health. 2026;8:1708289.
    PubMed    
    Abstract available
    
    

41. ZHANG L, Gong Y, Chen J, Li M, et al
    Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
    Front Immunol. 2026;17:1561666.
    PubMed    
    Abstract available
    
    

42. KUCAN BRLIC P, Bellulovich E, Golemac M, Jaksic A, et al
    High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread.
    Front Immunol. 2026;17:1754848.
    PubMed    
    Abstract available
    
    

43. MUNERA-MARAVILLA E, Perez-Escavy M, Rubio C, Segovia C, et al
    Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
    J Exp Clin Cancer Res. 2026 Feb 23. doi: 10.1186/s13046-026-03677.
    PubMed    
    
    
    

44. CUI J, Chen S, Liu X, Jiang X, et al
    PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.
    Cell Death Dis. 2026 Feb 23. doi: 10.1038/s41419-026-08498.
    PubMed    
    Abstract available
    
    

45. SEO J, Park JM, Park DJ, Seo I, et al
    Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jan 23:102513. doi: 10.1016/j.clgc.2026.102513.
    PubMed    
    Abstract available
    
    

46. XU L, Lin Y, Shi G, Zhang L, et al
    Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment.
    J Biol Chem. 2026 Feb 20:111304. doi: 10.1016/j.jbc.2026.111304.
    PubMed    
    Abstract available
    
    

47. MISURKA J, Berjaoui MB, Lajkosz K, Cockburn J, et al
    PA- versus urologist-performed flexible cystoscopy: A comparative study.
    JAAPA. 2026;39:34-36.
    PubMed    
    Abstract available
    
    

48. LUO C, Kuang X, Dai Y, Cai Z, et al
    DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
    Clin Epigenetics. 2026 Feb 21. doi: 10.1186/s13148-026-02079.
    PubMed    
    Abstract available
    
    

49. XU DM, Chen J, Lin SB, Xu TY, et al
    ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
    J Transl Med. 2026 Feb 21. doi: 10.1186/s12967-026-07830.
    PubMed    
    
    
    

50. CHEN Q, Wu K, Cai B, Yu X, et al
    LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
    World J Surg Oncol. 2026 Feb 21. doi: 10.1186/s12957-026-04246.
    PubMed    
    
    
    

51. FALQUET M, El Ahanidi H, Gomez-Cadena A, Su Z, et al
    Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.
    Nat Commun. 2026 Feb 21. doi: 10.1038/s41467-026-69841.
    PubMed    
    Abstract available
    
    

52. STEMPEL MH, Quezada JP, Belz B, Sun F, et al
    Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.
    Urol Oncol. 2026 Feb 20:111005. doi: 10.1016/j.urolonc.2026.111005.
    PubMed    
    Abstract available
    
    

53. DI LORENZO G, Di Maio M, Buonerba C
    Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
    Oncol Ther. 2026 Feb 21. doi: 10.1007/s40487-026-00417.
    PubMed    
    Abstract available
    
    

54. CHEN C, Yang Y, Niu H, Tang Y, et al
    Interfacial Electric Locking of the Aptamer Conformation for Accurate Liquid Biopsy Detection.
    Nano Lett. 2026;26:2371-2380.
    PubMed    
    Abstract available
    
    

55. SAKTHIVEL DK, Prabhakar P, Iyub MJR, Garje R, et al
    Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study.
    Clin Genitourin Cancer. 2026;24:102495.
    PubMed    
    Abstract available
    
    

56. TAWAGI K, Khaki AR, Chablani PV, Hoffman-Censits J, et al
    Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
    Clin Genitourin Cancer. 2026;24:102487.
    PubMed    
    Abstract available
    
    

57. SAHIN KC, Simsekoglu MF, Ozden SB, Ercili B, et al
    Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights.
    Surg Oncol. 2026;64:102344.
    PubMed    
    Abstract available
    
    

58. HUNDEBOLL JH, Olesen AF, Wessel I, Magkos F, et al
    Not just about weight: Identifying hidden nutritional vulnerability after radical cystectomy.
    Eur J Clin Nutr. 2025 Dec 10. doi: 10.1038/s41430-025-01694.
    PubMed    
    Abstract available
    
    

59. PAN W, Xing J, Chen X, Xue R, et al
    Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.
    Int J Surg. 2026;112:4762-4788.
    PubMed    
    Abstract available
    
    

60. WENG HW, Ting HK, Wang HH, Peng TJ, et al
    Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.
    J Transl Med. 2026 Mar 4. doi: 10.1186/s12967-026-07943.
    PubMed    
    
    
    

61. ROUPRET M
    Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladd
    Ann Oncol. 2026 Mar 3:S0923-7534(26)00046-3. doi: 10.1016/j.annonc.2026.
    PubMed    
    
    
    

62. ZHOU M, Xue X, Li H, Chen Z, et al
    Decoding the metabolic-immune axis for novel therapeutics in bladder cancer.
    Biochim Biophys Acta Rev Cancer. 2026 Mar 2:189569.
    PubMed    
    Abstract available
    
    

63. YANG M, Chai X, Ye D, Zhao A, et al
    Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin immunotherapy.
    J Med Econ. 2026;29:672-687.
    PubMed    
    Abstract available
    
    

64. BANG S, Joo SM, Kim DK, Kwon JK, et al
    Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences.
    Investig Clin Urol. 2026;67:162-169.
    PubMed    
    Abstract available
    
    

65. YANG Q, Zhou D, Beasley A, Liu Y, et al
    Identification of SLC3A2 as a Potential Therapeutic Target of Ferroptosis in Bladder Cancer.
    Arch Esp Urol. 2026;79:36-48.
    PubMed    
    Abstract available
    
    

66. MCKAY RR, Tipirneni A, Bangs R, Guercio BJ, et al
    Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.
    Am Soc Clin Oncol Educ Book. 2026;46:e516902.
    PubMed    
    Abstract available
    
    

67. GIRGIN R, Mungan NA
    Turkish urologists' knowledge and attitudes on lifestyle advice for bladder cancer: a national survey.
    Support Care Cancer. 2026;34:260.
    PubMed    
    Abstract available
    
    

68. YAMADA S, Sato M, Osawa T, Harabayashi T, et al
    Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.
    Cancer Sci. 2026;117:739-748.
    PubMed    
    Abstract available
    
    

69. NOGUEIRA CM, Machado C, Santos RB, Faustino AS, et al
    Infiltrated penile papules as a cutaneous manifestation of disseminated BCGitis: A rare dermatologic presentation.
    Int J STD AIDS. 2026;37:444-446.
    PubMed    
    Abstract available
    
    

70. STARRETT JH, Allen EL, Neal M, Iyer S, et al
    Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
    Mol Cancer Ther. 2026;25:408-415.
    PubMed    
    Abstract available
    
    

71. SHUKLA A, Hiralal, Raj H, Surekha S, et al
    Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in bladder cancer: Insight from a prospective tertiary care study.
    Urologia. 2026 Mar 13:3915603261429445. doi: 10.1177/03915603261429445.
    PubMed    
    Abstract available
    
    

72. TAN K, Quan X, Tan M, Han Z, et al
    Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report.
    Front Oncol. 2026;16:1734661.
    PubMed    
    Abstract available
    
    

73. WANG X, Zhao J, Li Q, Chang J, et al
    Disulfidptosis and androgenic cancers: from molecular mechanisms to clinical applications and future translational research.
    Front Endocrinol (Lausanne). 2026;17:1783929.
    PubMed    
    Abstract available
    
    

74. LI Z, Yu Y, Liu F, Wu Y, et al
    Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
    Sci Rep. 2026 Mar 13. doi: 10.1038/s41598-026-42815.
    PubMed    
    Abstract available
    
    

75. HERMANN-VARADI M
    [Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors].
    Magy Onkol. 2026;70:85-87.
    PubMed    
    Abstract available
    
    

76. PULUGOR GD, Galdi A, Varga L, Jorgo K, et al
    [Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].
    Magy Onkol. 2026;70:23-31.
    PubMed    
    Abstract available
    
    

77. CERBONE L, Roviello G, Calabro F, Taha T, et al
    Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
    Front Immunol. 2026;17:1667155.
    PubMed    
    Abstract available
    
    

78. HAO Z, Zhu L, Ding J, Jin Q, et al
    bp-VI-RADS combined with normalized apparent diffusion coefficient enhances diagnostic efficacy for muscle-invasive bladder cancer.
    Quant Imaging Med Surg. 2026;16:244.
    PubMed    
    Abstract available
    
    

79. LIU W, Xiao J, Zou J, He Z, et al
    Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.
    Asian J Urol. 2026;13:11-23.
    PubMed    
    Abstract available
    
    

80. LIU S, Wang M, Wang W
    [Analysis of urine biomarkers in urothelial carcinoma based on untargeted metabolomics].
    Se Pu. 2026;44:329-337.
    PubMed    
    Abstract available
    
    

81. MANCIN S, Ferrara G, Palomares SM, Matteucci S, et al
    Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-Analysis.
    Cancer Med. 2026;15:e71672.
    PubMed    
    Abstract available
    
    

82. LODEWIJK I, Rubio C, Eriksson P, Reina IA, et al
    CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.
    Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-42566.
    PubMed    
    
    
    

83. BOLENZ C, Heidenreich A
    [From limited options to individualized strategies: advances in the treatment of bladder cancer].
    Urologie. 2026;65:239-241.
    PubMed    
    
    
    

84. JIANG Y, Li J, Yang Z, Ma M, et al
    Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
    Cancer Immunol Immunother. 2026;75:103.
    PubMed    
    Abstract available
    
    

85. MASON B, Eccleston A, Ayala-Nunes L, Hauber B, et al
    Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
    Patient. 2026 Mar 11. doi: 10.1007/s40271-026-00804.
    PubMed    
    Abstract available
    
    

86. ITO K, Yamashita R, Kasai S, Sakura Y, et al
    A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.
    IJU Case Rep. 2026;9:e70155.
    PubMed    
    Abstract available
    
    

87. FAN G, Luo X, Li K, Zhang Z, et al
    Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
    Asian J Pharm Sci. 2025;20:101095.
    PubMed    
    Abstract available
    
    

88. LIANG S, Liu H, Su Q, Li X, et al
    Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor.
    Transl Androl Urol. 2026;15:46.
    PubMed    
    Abstract available
    
    

89. LIU J, Tang X, Cui Y, Yang X, et al
    Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.
    Transl Androl Urol. 2026;15:60.
    PubMed    
    Abstract available
    
    

90. WANG Q, Pei CS, Cao JY, Peng H, et al
    Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    Cancer Manag Res. 2026;18:583762.
    PubMed    
    Abstract available
    
    

91. WISHAHI M
    Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.
    World J Gastrointest Pharmacol Ther. 2026;17:115573.
    PubMed    
    Abstract available
    
    

92. SU Y, Wu J, Deng Z, Luo Y, et al
    In Vivo Target Drug Enrichment Based on Spatiotemporal Acoustic Node Modulation (STANM) for Bladder Cancer Treatment.
    Adv Mater. 2026 Mar 10:e17740. doi: 10.1002/adma.202517740.
    PubMed    
    Abstract available
    
    

93. GAO Y, Yang F, Yin L, Wang W, et al
    A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in Bladder Cancer.
    ACS Nano. 2026 Mar 10. doi: 10.1021/acsnano.5c21831.
    PubMed    
    Abstract available
    
    

94. VAN CREIJ NCH, Tymoszuk P, Handle F, Seeber A, et al
    Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.
    Clin Transl Med. 2026;16:e70638.
    PubMed    
    Abstract available
    
    

95. QIN S, Luo H, Hong Y, Fu C, et al
    Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
    Abdom Radiol (NY). 2026 Mar 9. doi: 10.1007/s00261-026-05390.
    PubMed    
    Abstract available
    
    

96. DONMEZ K, Yorulmaz EM, Candemir E, Ozcan S, et al
    Unusual metastatic patterns of urologic malignancies: a case series and literature review.
    Can J Urol. 2026;33:211-219.
    PubMed    
    Abstract available
    
    

97. AKKAD A, Bruyere F, Bourgi A
    Uretero-enteric strictures after cystectomy: revealing the modifiable risk factors.
    Can J Urol. 2026;33:155-163.
    PubMed    
    Abstract available
    
    

98. ZHAN M, Zhou Z, Zhang J, Wang X, et al
    Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.
    Can J Urol. 2026;33:35-49.
    PubMed    
    Abstract available
    
    

99. NIE Q, Jiang M, Wan S, Xi M, et al
    Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target.
    PeerJ. 2026;14:e20917.
    PubMed    
    Abstract available
    
    

100. LI Z, Wang G, Tan S, Wang Y, et al
     Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with clinicopathological features.
     Front Oncol. 2026;16:1757293.
     PubMed    
     Abstract available
     
     

101. FENG R, Zhang J, Tao Y, Hou J, et al
     Correction: Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
     Front Oncol. 2026;16:1787982.
     PubMed    
     Abstract available
     
     

102. HUANG Z, Cao X, Yan Y, Li H, et al
     Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation.
     Int J Med Sci. 2026;23:986-1001.
     PubMed    
     Abstract available
     
     

103. ISTAMULOV M, Eriksson H, Abuhasanein S
     Standardized care pathway reshaped the diagnostic and therapeutic landscape of urinary bladder cancer. A 15-year population-based study.
     BJUI Compass. 2026;7:e70179.
     PubMed    
     Abstract available
     
     

104. MENGYAN J, Jun Q, Wen L, Tingting P, et al
     Research Progress on Financial Toxicity in Bladder Cancer Patients.
     J Surg Oncol. 2026 Mar 8. doi: 10.1002/jso.70201.
     PubMed    
     Abstract available
     
     

105. ZHANG Y, Liu L, Yang B, Wu Q, et al
     Electron transfer-driven ultrathin nanozyme synergizes with nucleic acid amplification for bladder cancer screening.
     Biosens Bioelectron. 2026;303:118580.
     PubMed    
     Abstract available
     
     

106. SONG YS, Liu CK, Jiang WS, Liu J, et al
     Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in bladder cancer by blocking Akt-SREBP1-SCD1 pathway.
     Phytomedicine. 2026;154:158011.
     PubMed    
     Abstract available
     
     

107. QIN Z, Zhou H, Hu Y, Xiong X, et al
     Survival prediction for bladder cancer using multimodal data with quantum neural networks and transformer architectures.
     Sci Rep. 2026 Mar 7. doi: 10.1038/s41598-026-42047.
     PubMed    
     Abstract available
     
     

108. LIJNEN RAG, Ringia JB, Claps F, Vogel WV, et al
     Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.
     Eur Urol Oncol. 2026 Mar 6:S2588-9311(26)00046-5. doi: 10.1016/j.euo.2026.
     PubMed    
     Abstract available
     
     

109. YAN H, Yin C, Xu F, Li R, et al
     Unraveling the connection between PFOA and bladder cancer: A study integrating network toxicology, molecular docking, and experimental validation.
     Toxicol Appl Pharmacol. 2026;511:117784.
     PubMed    
     Abstract available
     
     

110. NUR BUDAYA T, Seputra KP, Susianti H, Aditya Hutama S, et al
     Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection and Evaluation Method for Bladder Cancer.
     Asian Pac J Cancer Prev. 2026;27:911-920.
     PubMed    
     Abstract available
     
     

111. LI P, Li L, Li Z, Wang S, et al
     Correction: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.
     Cancer Cell Int. 2026;26:119.
     PubMed    
     
     
     

112. LI J, He Y, Wu S
     Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following Repeat Transurethral Resection: A Meta-Analysis.
     J Coll Physicians Surg Pak. 2026;36:87-94.
     PubMed    
     Abstract available
     
     

113. GUO X, Zhu C, Yin Z
     A positive SPTBN2-FLI1 feedback axis promotes bladder cancer via PI3K/AKT activation.
     Cell Signal. 2026 Mar 4:112471. doi: 10.1016/j.cellsig.2026.112471.
     PubMed    
     Abstract available
     
     

114. QI T, Yang W, Liu R, Deng D, et al
     SWI/SNF-associated molecular subtypes reshape tumor microenvironmental features and inform precision therapeutic strategies in bladder cancer.
     Front Cell Infect Microbiol. 2026;16:1774929.
     PubMed    
     Abstract available
     
     

115. CAO JY, Peng H, Wang GY, Chang PA, et al
     IGF2BP3 promotes the muscle invasion of bladder cancer via PPARgamma dysregulation.
     Discov Oncol. 2026 Mar 5. doi: 10.1007/s12672-026-04648.
     PubMed    
     
     
     

116. KHAN A, Alanazi FJ, Ahmed S, Alzahrani AR, et al
     Glycoprotein biomarkers for bladder cancer detection.
     Clin Chim Acta. 2026;586:120938.
     PubMed    
     Abstract available
     
     

117. TANGUY M, Armelle P, Sheik E, Nicolas I, et al
     Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study.
     Fr J Urol. 2026 Mar 3:103093. doi: 10.1016/j.fjurol.2026.103093.
     PubMed    
     Abstract available
     
     

118. ZHANG M, Wang K, Li G, Bao X, et al
     Light-activated targeted degradation of VHL drug for selective tumor killing: A novel strategy for precision therapy of bladder cancer.
     Eur J Med Chem. 2026;309:118736.
     PubMed    
     Abstract available
     
     

119. GAO X, Liu J, Deng D, Xiao J, et al
     The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
     Int Immunopharmacol. 2026;175:116443.
     PubMed    
     Abstract available
     
     

120. AJALLI MM, Sansebli Y, Ekrami D, Alaeenejad F, et al
     Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.
     Clin Exp Med. 2026 Mar 5. doi: 10.1007/s10238-026-02098.
     PubMed    
     
     
     

121. TIAN X, Liu Y, Mi Z, Liang Y, et al
     CALR/HIF-1alpha Positive Feedback Loop Drives CALR Upregulation to Promote EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.
     Cancer Sci. 2026 Mar 5. doi: 10.1111/cas.70354.
     PubMed    
     Abstract available
     
     

122. 
     Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".
     Dis Markers. 2026;2026:9804137.
     PubMed    
     Abstract available
     
     

123. MALSHY K, Messing EM
     Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.
     Bladder Cancer. 2026;12:23523735261429862.
     PubMed    
     
     
     

124. HE J, Jiang Z, Peng S, Peng L, et al
     Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer.
     Mol Genet Genomics. 2026;301:50.
     PubMed    
     Abstract available
     
     

125. MIYAMOTO T, Miyake M, Nishimura N, Oda Y, et al
     Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
     Cureus. 2026;18:e102672.
     PubMed    
     Abstract available
     
     

126. HUANG J, Hu H, Sun M, Wu W, et al
     A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification.
     NPJ Digit Med. 2026 Mar 3. doi: 10.1038/s41746-026-02499.
     PubMed    
     Abstract available
     
     

127. DOMANSKI P, Hanusz K, Zapala L, Shah P, et al
     Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
     Clin Genitourin Cancer. 2026 Feb 11:102514. doi: 10.1016/j.clgc.2026.102514.
     PubMed    
     Abstract available
     
     

128. MENA E, Lindenberg L, Heng S, Choyke PL, et al
     Advances and challenges of PET imaging in bladder cancer-An update and future trends.
     Semin Nucl Med. 2026 Mar 2:S0001-2998(26)00046.
     PubMed    
     Abstract available
     
     

129. KUROBE M, Ogawa T, Satoh Y, Yamamoto M, et al
     Near infrared ray-guided partial cystectomy using da Vinci Firefly((R)) technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor.
     Investig Clin Urol. 2026;67:178-185.
     PubMed    
     Abstract available
     
     

130. YOON SG, Park TY, Jin HJ, Noh TI, et al
     Long-term oncologic outcomes of robot-assisted radical cystectomy: Prognostic indicators and complication profiles from a high-volume single-surgeon series.
     Investig Clin Urol. 2026;67:148-161.
     PubMed    
     Abstract available
     
     

131. CHOI SY, Yang YJ, Min KC, Lee YS, et al
     Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials.
     Investig Clin Urol. 2026;67:131-139.
     PubMed    
     Abstract available
     
     

132. AKIN Y, Yorulmaz EM, Gorgel SN, Ozcan S, et al
     Who is Next? Impact of Systemic Immune-Inflammation Index and De Ritis Ratio for Predicting 90-Day Survival after Salvage Cystectomy in Advanced Bladder Cancer.
     Arch Esp Urol. 2026;79:66-72.
     PubMed    
     Abstract available
     
     

133. SARI H, Celik S, Yorukoglu K, Celebi I, et al
     Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
     Arch Esp Urol. 2026;79:58-65.
     PubMed    
     Abstract available
     
     

134. 
     Strategy to Analyze Urine Tumor DNA Predicts Outcomes in Bladder Cancer.
     Cancer Discov. 2026 Feb 11:OF1. doi: 10.1158/2159-8290.CD-RW2026.
     PubMed    
     
     
     

135. SIDAWAY P
     Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.
     Nat Rev Clin Oncol. 2026 Mar 2. doi: 10.1038/s41571-026-01139.
     PubMed    
     
     
     

136. BARLAK BSR, Iskender B
     Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
     Cancer Genomics Proteomics. 2026;23:300-321.
     PubMed    
     Abstract available
     
     

137. NECCHI A, Maiorano BA, de Jong JJ, Proudfoot JA, et al
     Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
     Lancet Oncol. 2026 Feb 27:S1470-2045(26)00050.
     PubMed    
     Abstract available
     
     

138. WONG R, Matulewicz RS, Talwar R, Goldstein AO, et al
     Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.
     JCO Oncol Pract. 2026 Mar 2:OP2500780. doi: 10.1200/OP-25-00780.
     PubMed    
     Abstract available
     
     

139. SUPERDOCK M, Wobker SE, Carmicheal I, Kim WY, et al
     Computational pathology in bladder cancer: A scoping review.
     Bladder Cancer. 2026;12:23523735251413333.
     PubMed    
     Abstract available
     
     

140. BLUMENFELD P, Levy D, Hillman Y, Feldman J, et al
     Daily artificial intelligence-assisted adaptive small margin radiotherapy during trimodal therapy of muscle-invasive bladder cancer.
     Front Oncol. 2026;16:1729810.
     PubMed    
     Abstract available
     
     

141. IMAI K, Masuda N, Hazama T, Hosomi T, et al
     Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
     IJU Case Rep. 2026;9:e70157.
     PubMed    
     Abstract available
     
     

142. MEEKS JJ
     The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
     J Clin Invest. 2026;136:e202079.
     PubMed    
     Abstract available
     
     

143. MOINARD-BUTOT F, Barbe-Richaud JB, Baudry E, Pierard L, et al
     Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
     Urol Oncol. 2026;44:111036.
     PubMed    
     Abstract available
     
     

144. CUADRA JDP, Perez MA, Gonzalez-Peramato P, Sanz J, et al
     PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era.
     Pathol Res Pract. 2026;281:156372.
     PubMed    
     Abstract available
     
     

145. THU PHUNG TA, Weng R, Black PC, Dyrskjot L, et al
     A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.
     Eur Urol Oncol. 2026 Feb 27:S2588-9311(26)00057.
     PubMed    
     Abstract available
     
     

146. PRIETO MATIENZO L, Fischer-Straub A, Perera M, Babst C, et al
     Follicular lymphoma of the urachus.
     BMJ Case Rep. 2026;19:e267211.
     PubMed    
     Abstract available
     
     

147. BENCINA G, Ruiz RA, Bencina B
     Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework.
     J Cancer Policy. 2026;48:100728.
     PubMed    
     Abstract available
     
     

148. HUANG J, Ojo A, Liaw B
     Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.
     Curr Oncol. 2026;33:103.
     PubMed    
     Abstract available
     
     

149. BURTZ M, Boss MK, Leary D, Martin TW, et al
     Radiation therapy as a treatment for urinary obstruction secondary to urothelial carcinoma in dogs.
     J Vet Intern Med. 2026;40:aalaf093.
     PubMed    
     Abstract available
     
     

150. SONG SH, Park JH, Lee S, Jeong SH, et al
     Oncological outcomes of concurrent nephroureterectomy during radical cystectomy: A propensity score-matched analysis with multivariable adjustment from Korean multicenter database.
     Surg Oncol. 2026;65:102362.
     PubMed    
     Abstract available
     
     

151. GAISA NT, Reis H, Heidenreich A
     [Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].
     Urologie. 2026;65:278-287.
     PubMed    
     Abstract available
     
     

152. WEI G, Fan ZH, Huang RZ, Wei Y, et al
     Design, synthesis and antitumor activity evaluation of 1,4-naphthoquinone-benzene sulfonamide hybrids.
     Future Med Chem. 2026;18:637-648.
     PubMed    
     Abstract available
     
     

153. ZHANG Q, Hong Y, He C, Guo R, et al
     Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma.
     Biochim Biophys Acta Mol Basis Dis. 2026;1872:168182.
     PubMed    
     Abstract available
     
     

154. KOHLER J, Rodler S, Andersson J, Juptner M, et al
     [Innovative imaging techniques for urothelial carcinoma].
     Urologie. 2026;65:242-249.
     PubMed    
     Abstract available
     
     

155. KIMBALL J, Steele J, Vargas SO, Hirsch M, et al
     BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung Transplantation in Childhood.
     Pediatr Dev Pathol. 2026;29:128-135.
     PubMed    
     Abstract available
     
     

156. NIEGISCH G, Zschabitz S, Eckstein M, Klumper N, et al
     [From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma].
     Urologie. 2026;65:271-277.
     PubMed    
     Abstract available
     
     

157. ORDOBAZARI A, Nikfar R, Zhao X, Davaro E, et al
     Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria.
     Diagn Cytopathol. 2026;54:299-306.
     PubMed    
     Abstract available
     
     

158. FARTIYAL JS, Rao M, Elhence PA, Nalwa A, et al
     Comparison of Conventional Sediment Smears and Liquid-Based Cytology and Utility of Cell Block Preparation in Urinary Cytology.
     Diagn Cytopathol. 2026;54:285-292.
     PubMed    
     Abstract available
     
     

159. MAN X, Dong C, Dong A, Song X, et al
     FDG PET/CT in Primary Mucosa-associated Lymphoid Tissue Lymphoma of the Bladder.
     Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006295.
     PubMed    
     Abstract available
     
     

160. FORTIER A, Mokadem S, Saadi A, Gillibert A, et al
     Does ureteroileal anastomosis technique (Bricker versus Wallace) influence benign ureteroileal stricture occurrence on transileal diversion?
     Fr J Urol. 2026;36:103078.
     PubMed    
     Abstract available
     
     

161. SRETENOVIC M, Bumbasirevic U, Bojanic N, Durutovic O, et al
     Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients with Bladder Carcinoma Treated by Radical Cystectomy.
     Ann Surg Oncol. 2026;33:3743-3751.
     PubMed    
     Abstract available
     
     

162. CHEN C, An M, Zheng H, Pang M, et al
     B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.
     Cancer Cell. 2026;44:551-566.
     PubMed    
     Abstract available
     
     

163. COLLINS K, Gupta S, Cheng L
     Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.
     Hum Pathol. 2026;169:106018.
     PubMed    
     Abstract available
     
     

164. WANG Y, Wu N, Zhang F, Zhang S, et al
     The Comprehensive Complication Index for Assessing Short-Term Complications of Urothelial Carcinoma with Variant Histology: A Patient-Based Study.
     Ann Surg Oncol. 2026;33:3688-3697.
     PubMed    
     Abstract available
     
     

165. LONGONI M, Le QC, Falkenbach F, Marmiroli A, et al
     The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.
     Ann Surg Oncol. 2026;33:3680-3687.
     PubMed    
     Abstract available
     
     

166. D'AGOSTINO E, Pirola M, Callegari V, Tonni E, et al
     Future directions for antibody-drug conjugates in urothelial cancer.
     Expert Rev Anticancer Ther. 2026;26:321-332.
     PubMed    
     Abstract available
     
     

167. KEANE KG, Redfern A, Lim J, Hayne D, et al
     The role of gemcitabine-docetaxel in the management of NMIBC: a scoping review of current status and future directions.
     Expert Rev Anticancer Ther. 2026;26:333-344.
     PubMed    
     Abstract available
     
     

168. KEANE KG, Redfern A, Lim J, Hayne D, et al
     The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction.
     Expert Rev Anticancer Ther. 2026;26:307-320.
     PubMed    
     Abstract available
     
     

169. WOO S, Luk L, Muglia VF, Briganti A, et al
     VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee.
     Eur Radiol. 2026;36:1093-1104.
     PubMed    
     Abstract available
     
     

170. RIZKALLA CN, Tretiakova M, Williamson SR, Akgul M, et al
     Overlapping Morphologic and Immunophenotypic Features of Plasmacytoid Urothelial Carcinoma and Urothelial Carcinoma With Osteoclast-Like Giant Cells.
     Int J Surg Pathol. 2026;34:309-314.
     PubMed    
     Abstract available
     
     

171. SCHNEIDEWIND L, Kiss B, Arnold N, Kranz J, et al
     [Gender-specific differences in outcome and survival in early cystectomy : Systematic review].
     Urologie. 2026;65:300-307.
     PubMed    
     Abstract available
     
     

172. TUCKER J, Sharma V, Johnson M, Hibbert R, et al
     Safety and Diagnostic Yield of Percutaneous Urinary Bladder Tumor Biopsy.
     Abdom Radiol (NY). 2026;51:1444-1449.
     PubMed    
     Abstract available
     
     

173. DENG Z, Li M, Li J, Jung M, et al
     Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.
     J Racial Ethn Health Disparities. 2026;13:1555-1571.
     PubMed    
     Abstract available
     
     

174. GONG Z, He Y, Mi X, Li C, et al
     Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
     Aging (Albany NY). 2023;15:9479-9498.
     PubMed    
     Abstract available
     
     

175. XU C, Zou W, Wang Y, Liu X, et al
     Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.
     Crit Rev Oncol Hematol. 2023;191:104137.
     PubMed    
     Abstract available
     
     

176. GIESE M, Butea-Bocu M, Huber J, Groeben C, et al
     [Prehabilitation prior to radical cystectomy].
     Urologie. 2023;62:1034-1040.
     PubMed    
     Abstract available
     
     

177. OEY O, Tiong SS, Wong SL, Navadgi S, et al
     Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report.
     Folia Med (Plovdiv). 2023;65:693-698.
     PubMed    
     Abstract available
     
     

178. MENDES WEFELNBERG M, Reimer N, Baumann FT
     [Exercise therapy in prehabilitation : Current findings in urology].
     Urologie. 2023;62:1011-1016.
     PubMed    
     Abstract available
     
     

179. ANDO K, Kurashina R, Motoi N, Iizuka T, et al
     Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
     Biochem Biophys Res Commun. 2023;676:165-170.
     PubMed    
     Abstract available
     
     

180. ZHANG J, Guo F, Zhu J, He Z, et al
     Ultrasensitive Electrochemiluminescence Immunosensor for Bladder Marker Human Complement Factor H-Related Protein Detection.
     Anal Chem. 2023;95:11440-11448.
     PubMed    
     Abstract available
     
     

181. PERUZZI V, Torresan S, Cortiula F, Fanelli M, et al
     Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical Reasoning: An Illustrative Case-based Discussion.
     Curr Probl Diagn Radiol. 2023;52:478-481.
     PubMed    
     Abstract available
     
     

182. LU S, Zhang X, Cai Z, Xi Z, et al
     Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs in bladder urothelial carcinoma.
     J Biochem Mol Toxicol. 2023;37:e23441.
     PubMed    
     Abstract available
     
     

183. YAMASHITA S, Wada T, Deguchi R, Mashima N, et al
     Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab.
     Jpn J Clin Oncol. 2023;53:845-850.
     PubMed    
     Abstract available
     
     

184. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
     Aligning bladder cancer research with patient needs: an update on research priorities.
     BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
     PubMed    
     
     
     

185. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
     Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
     BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
     PubMed    
     Abstract available
     
     

186. BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
     Is there still a role for ureteric frozen section analysis during radical cystectomy?
     BJU Int. 2026;137:659-666.
     PubMed    
     Abstract available
     
     

187. BRYAN RT, Patel K, Ward DG
     The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
     BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
     PubMed    
     
     
     

188. FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
     Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
     BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
     PubMed    
     Abstract available
     
     

189. DAY E, Bizzarri FP, Waine E, Martin R, et al
     Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
     BJU Int. 2026;137:708-715.
     PubMed    
     Abstract available
     
     

190. PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
     Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
     BJU Int. 2026;137:684-689.
     PubMed    
     Abstract available
     
     

191. GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
     Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
     Cancer Res. 2023;83:3340-3353.
     PubMed    
     Abstract available
     
     

192. GONZALEZ-PADILLA DA, Subiela JD, Guerrero-Ramos F, Pichler R, et al
     Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.
     Curr Opin Urol. 2026 Mar 4. doi: 10.1097/MOU.0000000000001373.
     PubMed    
     Abstract available
     
     

193. CLARK PE
     Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
     Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

194. NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
     Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
     Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

195. LIU P, Chen J, Zhou J
     Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

196. GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
     Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
     Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

197. SANO T, Ohe C, Motoki Y, Nakamoto T, et al
     Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
     Int J Urol. 2026;33:e70392.
     PubMed    
     Abstract available
     
     

198. PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
     Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
     Int Urol Nephrol. 2026;58:921-929.
     PubMed    
     Abstract available
     
     

199. NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
     Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
     Int Urol Nephrol. 2026;58:861-871.
     PubMed    
     Abstract available
     
     

200. ZHENG Q, Liao E, Chen D, Shan G, et al
     Bladder cancer organoids: bridging pathological features and drug response for precision oncology.
     Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
     PubMed    
     Abstract available
     
     

201. THAKKER PU, Refugia JM, Casals R, Able C, et al
     Stent-free rates in cutaneous ureterostomy urinary diversion after radical cystectomy.
     Int Urol Nephrol. 2023;55:2809-2814.
     PubMed    
     Abstract available
     
     

202. KAMAT AM, Hensley PJ, Maiorano BA, Li R, et al
     Bacillus Calmette-Guerin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naive Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
     J Clin Oncol. 2026 Mar 2:JCO2502670. doi: 10.1200/JCO-25-02670.
     PubMed    
     
     
     

203. UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
     Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical
     J Urol. 2026;215:441-449.
     PubMed    
     Abstract available
     
     

204. ZHANG L, Cao J, Gao Z, Han C, et al
     Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
     BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
     PubMed    
     
     
     

205. GAO WB, Yu JJ
     Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
     BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
     PubMed